Enanta Pharmaceuticals (ENTA) EBIT Margin (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported EBIT Margin of 69.07% for Q1 2026, up 9525.0% on a YoY basis from 0.72% in Q1 2025, and down 14.26% quarter-over-quarter from 60.45% in Q4 2025.
Enanta Pharmaceuticals (ENTA) EBIT Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported EBIT Margin for 15 years, with the latest figure at 69.07% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 9525.0% year-over-year to 69.07%; the trailing twelve-month figure through Mar 2026 stood at 87.24% (up 7116.0% YoY), and the FY2025 full-year result was 130.65%, up 4927.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 69.07%, down from 60.45% in the prior quarter.
- The five-year high for EBIT Margin was 60.45% in Q4 2025, with the low at 221.7% in Q1 2023.
- Historically, EBIT Margin has averaged 151.2% across 5 years, with a median of 163.9% in 2023.
- Annual changes were most pronounced in 2023 — EBIT Margin tumbled 6652 bps — and 2026, when it surged 9525 bps.
- Enanta Pharmaceuticals' EBIT Margin stood at 127.25% in 2022, then slumped by 52 bps to 193.78% in 2023, then rose by 28 bps to 138.82% in 2024, then jumped by 56 bps to 60.45% in 2025, then slipped by 14 bps to 69.07% in 2026.
- The last three EBIT Margin figures came in at 69.07% (Q1 2026), 60.45% (Q4 2025), and 121.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -69.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.07% |
| Dec 31, 2025 | -60.45% |
| Sep 30, 2025 | -121.56% |
| Jun 30, 2025 | -103.16% |
| Mar 31, 2025 | -164.32% |
| Dec 31, 2024 | -138.82% |
| Sep 30, 2024 | -204.38% |
| Jun 30, 2024 | -134.58% |
| Mar 31, 2024 | -192.13% |
| Dec 31, 2023 | -193.78% |
| Sep 30, 2023 | -163.90% |
| Jun 30, 2023 | -194.33% |
| Mar 31, 2023 | -221.70% |
| Dec 31, 2022 | -127.25% |
| Sep 30, 2022 | -133.13% |
| Jun 30, 2022 | -167.05% |
| Mar 31, 2022 | -180.85% |
| Dec 31, 2021 | -109.99% |
| Sep 30, 2021 | -143.06% |
| Jun 30, 2021 | -156.53% |